Immunogenicity and efficacy of CNA25 as a potential whole-cell vaccine against systemic candidiasis.

Disseminated fungal infections account for ~1.5 million deaths per year worldwide, and mortality may increase further due to a rise in the number of immunocompromised individuals and drug-resistance fungal species. Since an approved antifungal vaccine is yet to be available, this study explored the immunogenicity and vaccine efficacy of a DNA polymerase mutant strain of Candida albicans. CNA25 is a pol32ΔΔ strain that exhibits growth defects and does not cause systemic candidiasis in mice. Immunized mice with live CNA25 were fully protected against C. albicans and C. parapsilosis but partially against C. tropicalis and C. glabrata infections. CNA25 induced steady expression of TLR2 and Dectin-1 receptors leading to a faster recognition and clearance by the immune system associated with the activation of protective immune responses mostly mediated by neutrophils, macrophages, NK cells, B cells, and CD4⁺ and CD8⁺ T cells. Molecular blockade of Dectin-1, IL-17, IFNγ, and TNFα abolished resistance to reinfection. Altogether, this study suggested that CNA25 collectively activates innate, adaptive, and trained immunity to be a promising live whole-cell vaccine against systemic candidiasis. Synopsis: CNA25 is a DNA polymerase subunit knockout strain of pathogenic yeast Candida albicans. Immunization with live CNA25 prevents systemic candidiasis in mice. It is recognised by innate immune cells leading to its clearance. Activation of CD4+ and CD8 + T cells in vaccinated mice prevents fungal reinfection. Trained innate cells are also involved in protective immune responses. CNA25 is a DNA polymerase subunit knockout strain of pathogenic yeast Candida albicans. Immunization with live CNA25 prevents systemic candidiasis in mice. [ABSTRACT FROM AUTHOR]